Online Program

339225
State variations of risky drinking among cancer survivors and individuals with no cancer history: NHIS 1997-2010


Monday, November 2, 2015 : 3:06 p.m. - 3:24 p.m.

Stacey L. Tannenbaum, PhD, RD, LD/N, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL
Laura A. McClure, MSPH, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
Diana Kachan, PhD, Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, FL
William G. LeBlanc, PhD, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL
David J. Lee, PhD, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL
Background: Although moderate consumption of alcohol has been shown to impart some benefits to cancer survivors, risky drinking can be harmful and has not been studied in cancer survivors compared with individuals with no cancer history (non-survivors). We examined state-level prevalence of risky drinking among cancer survivors compared to non-survivors to help determine where limited resources could be utilized.

Methods: Pooled data from the 1997-2010 National Health Interview Survey were used to determine state-level prevalence of risky drinking among cancer survivors and non-survivors. Risky drinking was defined as ten or more drinks/week in men and seven or more drinks/week in women; or five or more drinks at one sitting, one or more times/year for both men and women. Two-tailed t-tests were used to compare each state for prevalence of risky drinking stratified by cancer survivor status. Data were adjusted for survey weights and analysis was performed using SUDAAN v10.

Results: Our sample included 15,802 cancer survivors and 226,649 non-survivors. Overall, cancer survivors were less likely to be risky drinkers than non-survivors 28.4% (SE=0.5) vs. 37.7% (SE=0.2); p<0.001, respectively. However, the exception to this was found in Louisiana where there was a non-significantly higher percentage of risky drinking in cancer survivors than in non-survivors (34.0% [SE=2.5] vs. 31.1% [SE=2.1], respectively; p=0.76). For cancer survivors the highest prevalence of risky drinking was found in Utah (37.9%; SE=5.9) and Kentucky (37.8%; SE=3.2) and, for those without cancer, in Idaho (48.1; SE=3.1) and Utah (47.6; SE=1.5). The lowest prevalence was seen in Arkansas (19.5%; SE=4.9) and Nebraska (19.7%; SE=3.9) for cancer survivors and Delaware (24.5%; SE=2.1) and Rhode Island (26.5%; SE=2.3) for non-survivors.

Conclusion: Overall, the prevalence of risky drinking is exceedingly high, and much higher in non-survivors than in cancer survivors. As there are serious repercussions for risky drinking, whether a cancer survivor or not, targeted interventions to reduce this high risk behavior are warranted, particularly in Utah for everyone, Kentucky for cancer survivors, and Idaho and Iowa for non-survivors. Further research into cancer survivors in Louisiana is needed to determine why cancer survivors have higher risky drinking behaviors than non-survivors.

Learning Areas:

Epidemiology
Other professions or practice related to public health
Provision of health care to the public

Learning Objectives:
Compare prevalence of risky drinking among cancer survivors by state of residence. Differentiate prevalence of risky drinking among cancer survivors and those without a history of cancer by state of residence. Identify states where the prevalence of risky drinking is exceptionally high or lowest among cancer survivors and those without a history of cancer.

Keyword(s): Alcohol Use, Epidemiology

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been an Assistant Scientist working on multiple federally funded grants focused on the epidemiology of cancer survivors. I have first-authored several papers on cancer survivors and on risky behaviors which included risky drinking.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.